Atezolizumab and hyaluronidase-tqjs is approved by FDA for subcutaneous injection

Atezolizumab and hyaluronidase-tqjs is approved by FDA for subcutaneous injection

Share This Post

On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications corresponding to the intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc.), encompassing non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS). Refer to the prescribed information for the particular indications.

Effectiveness and Safety

The subcutaneous administration of atezolizumab and hyaluronidase-tqjs was assessed in IMscin001 (NCT03735121), an open-label, multicenter, international, randomized trial involving adult patients with locally advanced or metastatic NSCLC who had not previously received cancer immunotherapy and exhibited disease progression after platinum-based chemotherapy. A total of 371 patients were randomized in a 2:1 ratio to receive subcutaneous atezolizumab with hyaluronidase-tqjs or intravenous atezolizumab until disease progression or intolerable toxicity occurred.

The principal outcome measure was atezolizumab exposure, accompanied by coprimary pharmacokinetic (PK) endpoints of Cycle 1 Ctrough and AUC0-21days. Supplementary descriptive efficacy outcome metrics were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The geometric mean ratio (GMR) (90% CI) of subcutaneous atezolizumab to intravenous atezolizumab for Cycle 1 Ctrough was 1.05 (0.88, 1.24), and for AUC0-21days it was 0.87 (0.83, 0.92), both of which exceeded the pre-specified criterion of 0.8 for comparability, hence satisfying the lower limit of the GMR (90% CI).

No significant variations in overall response rate, progression-free survival, or overall survival were detected across the various formulations. The confirmed overall response rate (ORR) was 9% (95% confidence interval: 5, 13) in the subcutaneous atezolizumab and hyaluronidase-tqjs group, and 8% (95% confidence interval: 4, 14) in the intravenous atezolizumab group.

The predominant adverse effects of any severity (≥ 10%) included fatigue, musculoskeletal pain, cough, dyspnea, and diminished appetite.

The advised dosage is a single 15 mL injection (comprising 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) delivered subcutaneously in the thigh over about 7 minutes every 3 weeks.

+ posts

Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. His career is marked by significant contributions to stem cell biology, developmental biology, and innovative research techniques.

Research Highlights

Dr. Mittal's research has focused on several key areas:

1) Cardiovascular Development and Regeneration: He studied coronary vessel development and regeneration using zebrafish models1.

2) Cancer Biology: At Dartmouth College, he developed zebrafish models for studying tumor heterogeneity and clonal evolution in pancreatic cancer.
3) Developmental Biology: His doctoral work at Keio University involved identifying and characterizing medaka fish mutants with cardiovascular defects.

4) Stem Cell Research: He investigated the effects of folic acid on mouse embryonic stem cells and worked on cryopreservation techniques for hematopoietic stem cells.

Publications and Presentations

Dr. Mittal has authored several peer-reviewed publications in reputable journals such as Scientific Reports, Cardiovascular Research, and Disease Models & Mechanisms1. He has also presented his research at numerous international conferences, including the Stanford-Weill Cornell Cardiovascular Research Symposium and the Weinstein Cardiovascular Development Conference.

In summary, Dr. Nishant Mittal is a dedicated and accomplished researcher with a strong track record in cardiovascular and cancer biology, demonstrating expertise in various model systems and a commitment to advancing scientific knowledge through innovative research approaches.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟